By Debdeep Gupta | 04 Jun, 2025
SPARC shares crash 19?ter Psoriasis drug fails to deliver in trials
SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company will halt further development and assess next stepsShares of Sun Pharma Advanced Research Company (SPARC), the research arm of India’s largest drugmaker Sun Pharma, plunged 19 percent to Rs 158 apiece on June 4 following disappointing Phase 2 trial results of its investigatio...